Enhancing poxvirus vectors vaccine immunogenicity

References

• Fauci AS. The global challenge of infectious diseases: the evolving role of the National Institutes of Health in basic and clinical research. Nat Immunol 2005; 6:743 - 7; http://dx.doi.org/10.1038/ni0805-743; PMID: 16034426
   PubMed Web of Science ®Google Scholar
• Mackett M, Smith GL, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A 1982; 79:7415 - 9; http://dx.doi.org/10.1073/pnas.79.23.7415; PMID: 6296831
   PubMed Web of Science ®Google Scholar
• Panicali D, Paoletti E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A 1982; 79:4927 - 31; http://dx.doi.org/10.1073/pnas.79.16.4927; PMID: 6289324
   PubMed Web of Science ®Google Scholar
• Boukhebza H, Bellon N, Limacher JM, Inchauspé G. Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines. Hum Vaccin Immunother 2012; 8:1746 - 57; http://dx.doi.org/10.4161/hv.21689; PMID: 22894957
   PubMed Web of Science ®Google Scholar
• Cottingham MG, Carroll MW. Recombinant MVA vaccines: dispelling the myths. Vaccine 2013; 31:4247 - 51; http://dx.doi.org/10.1016/j.vaccine.2013.03.021; PMID: 23523407
   PubMed Web of Science ®Google Scholar
• Draper SJ, Cottingham MG, Gilbert SC. Utilizing poxviral vectored vaccines for antibody induction-progress and prospects. Vaccine 2013; 31:4223 - 30; http://dx.doi.org/10.1016/j.vaccine.2013.05.091; PMID: 23746455
   PubMed Web of Science ®Google Scholar
• Gilbert SC. Clinical development of Modified Vaccinia virus Ankara vaccines. Vaccine 2013; 31:4241 - 6; http://dx.doi.org/10.1016/j.vaccine.2013.03.020; PMID: 23523410
   PubMed Web of Science ®Google Scholar
• Gómez CE, Nájera JL, Krupa M, Perdiguero B, Esteban M. MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther 2011; 11:189 - 217; http://dx.doi.org/10.2174/156652311795684731; PMID: 21453284
   PubMed Web of Science ®Google Scholar
• Gómez CE, Perdiguero B, Garcia-Arriaza J, Esteban M. Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother 2012; 8:1192 - 207; http://dx.doi.org/10.4161/hv.20778; PMID: 22906946
   PubMed Web of Science ®Google Scholar
• Gómez CE, Perdiguero B, García-Arriaza J, Esteban M. Clinical applications of attenuated MVA poxvirus strain. Expert Rev Vaccines 2013; 12:1395 - 416; http://dx.doi.org/10.1586/14760584.2013.845531; PMID: 24168097
   PubMed Web of Science ®Google Scholar
• Hill AV, Reyes-Sandoval A, O’Hara G, Ewer K, Lawrie A, Goodman A, Nicosia A, Folgori A, Colloca S, Cortese R, et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 2010; 6:78 - 83; http://dx.doi.org/10.4161/hv.6.1.10116; PMID: 20061802
   PubMed Web of Science ®Google Scholar
• Izzi V, Buler M, Masuelli L, Giganti MG, Modesti A, Bei R. Poxvirus-based vaccines for cancer immunotherapy: new insights from combined cytokines/co-stimulatory molecules delivery and “uncommon” strains. Anticancer Agents Med Chem 2014; 14:183 - 9; http://dx.doi.org/10.2174/18715206113136660376; PMID: 24237219
   PubMed Web of Science ®Google Scholar
• Kim JW, Gulley JL. Poxviral vectors for cancer immunotherapy. Expert Opin Biol Ther 2012; 12:463 - 78; http://dx.doi.org/10.1517/14712598.2012.668516; PMID: 22413824
   PubMed Web of Science ®Google Scholar
• Kreijtz JH, Gilbert SC, Sutter G. Poxvirus vectors. Vaccine 2013; 31:4217 - 9; http://dx.doi.org/10.1016/j.vaccine.2013.06.073; PMID: 23834812
   PubMed Web of Science ®Google Scholar
• Pantaleo G, Esteban M, Jacobs B, Tartaglia J. Poxvirus vector-based HIV vaccines. Curr Opin HIV AIDS 2010; 5:391 - 6; http://dx.doi.org/10.1097/COH.0b013e32833d1e87; PMID: 20978379
   PubMed Web of Science ®Google Scholar
• Volz A, Sutter G. Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies. Vaccine 2013; 31:4235 - 40; http://dx.doi.org/10.1016/j.vaccine.2013.03.016; PMID: 23523402
   PubMed Web of Science ®Google Scholar
• Walsh SR, Dolin R. Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert Rev Vaccines 2011; 10:1221 - 40; http://dx.doi.org/10.1586/erv.11.79; PMID: 21854314
   PubMed Web of Science ®Google Scholar
• Li S, Rodrigues M, Rodriguez D, Rodriguez JR, Esteban M, Palese P, Nussenzweig RS, Zavala F. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci U S A 1993; 90:5214 - 8; http://dx.doi.org/10.1073/pnas.90.11.5214; PMID: 7685119
   PubMed Web of Science ®Google Scholar
• Miyahira Y, García-Sastre A, Rodriguez D, Rodriguez JR, Murata K, Tsuji M, Palese P, Esteban M, Zavala F, Nussenzweig RS. Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice. Proc Natl Acad Sci U S A 1998; 95:3954 - 9; http://dx.doi.org/10.1073/pnas.95.7.3954; PMID: 9520474
   PubMed Web of Science ®Google Scholar
• Zavala F, Rodrigues M, Rodriguez D, Rodriguez JR, Nussenzweig RS, Esteban M. A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8(+) T cells. Virology 2001; 280:155 - 9; http://dx.doi.org/10.1006/viro.2000.0792; PMID: 11162829
   PubMed Web of Science ®Google Scholar
• González-Aseguinolaza G, Nakaya Y, Molano A, Dy E, Esteban M, Rodríguez D, Rodríguez JR, Palese P, García-Sastre A, Nussenzweig RS. Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii. J Virol 2003; 77:11859 - 66; http://dx.doi.org/10.1128/JVI.77.21.11859-11866.2003; PMID: 14557672
   PubMed Web of Science ®Google Scholar
• Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012; 482:89 - 93; http://dx.doi.org/10.1038/nature10766; PMID: 22217938
   PubMed Web of Science ®Google Scholar
• Boyd AC, Ruiz-Hernandez R, Peroval MY, Carson C, Balkissoon D, Staines K, Turner AV, Hill AV, Gilbert SC, Butter C. Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus. Vaccine 2013; 31:670 - 5; http://dx.doi.org/10.1016/j.vaccine.2012.11.047; PMID: 23200938
   PubMed Web of Science ®Google Scholar
• Ratto-Kim S, Currier JR, Cox JH, Excler JL, Valencia-Micolta A, Thelian D, Lo V, Sayeed E, Polonis VR, Earl PL, et al. Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens. PLoS One 2012; 7:e45840; http://dx.doi.org/10.1371/journal.pone.0045840; PMID: 23049876
   PubMed Web of Science ®Google Scholar
• Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, Nicosia A, Colloca S, Cortese R, Hill AV. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 2010; 78:145 - 53; http://dx.doi.org/10.1128/IAI.00740-09; PMID: 19858306
   PubMed Web of Science ®Google Scholar
• Reyes-Sandoval A, Rollier CS, Milicic A, Bauza K, Cottingham MG, Tang CK, Dicks MD, Wang D, Longley RJ, Wyllie DH, et al. Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity. Mol Ther 2012; 20:1633 - 47; http://dx.doi.org/10.1038/mt.2012.25; PMID: 22354374
   PubMed Web of Science ®Google Scholar
• Gómez CE, Nájera JL, Jiménez EP, Jiménez V, Wagner R, Graf M, Frachette MJ, Liljeström P, Pantaleo G, Esteban M. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 2007; 25:2863 - 85; http://dx.doi.org/10.1016/j.vaccine.2006.09.090; PMID: 17113200
   PubMed Web of Science ®Google Scholar
• Mooij P, Balla-Jhagjhoorsingh SS, Koopman G, Beenhakker N, van Haaften P, Baak I, Nieuwenhuis IG, Kondova I, Wagner R, Wolf H, et al. Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J Virol 2008; 82:2975 - 88; http://dx.doi.org/10.1128/JVI.02216-07; PMID: 18184713
   PubMed Web of Science ®Google Scholar
• Vaccari M, Keele BF, Bosinger SE, Doster MN, Ma ZM, Pollara J, Hryniewicz A, Ferrari G, Guan Y, Forthal DN, et al. Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. J Virol 2013; 87:3538 - 48; http://dx.doi.org/10.1128/JVI.02863-12; PMID: 23325681
   PubMed Web of Science ®Google Scholar
• Santra S, Sun Y, Parvani JG, Philippon V, Wyand MS, Manson K, Gomez-Yafal A, Mazzara G, Panicali D, Markham PD, et al. Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors. J Virol 2007; 81:8563 - 70; http://dx.doi.org/10.1128/JVI.00744-07; PMID: 17553898
   PubMed Web of Science ®Google Scholar
• Abaitua F, Rodríguez JR, Garzón A, Rodríguez D, Esteban M. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Virus Res 2006; 116:11 - 20; http://dx.doi.org/10.1016/j.virusres.2005.08.008; PMID: 16214252
   PubMed Web of Science ®Google Scholar
• Gherardi MM, Ramírez JC, Esteban M. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide. J Virol 2000; 74:6278 - 86; http://dx.doi.org/10.1128/JVI.74.14.6278-6286.2000; PMID: 10864637
   PubMed Web of Science ®Google Scholar
• Gherardi MM, Ramirez JC, Rodríguez D, Rodríguez JR, Sano G, Zavala F, Esteban M. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. J Immunol 1999; 162:6724 - 33; PMID: 10352291
   PubMed Web of Science ®Google Scholar
• Gonzalo RM, Rodríguez JR, Rodríguez D, González-Aseguinolaza G, Larraga V, Esteban M. Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36. Microbes Infect 2001; 3:701 - 11; http://dx.doi.org/10.1016/S1286-4579(01)01426-5; PMID: 11489418
   PubMed Web of Science ®Google Scholar
• Nemeckova S, Sroller V, Hainz P, Krystofova J, Smahel M, Kutinova L. Experimental therapy of HPV16 induced tumors with IL12 expressed by recombinant vaccinia virus in mice. Int J Mol Med 2003; 12:789 - 96; PMID: 14533011
   PubMed Web of Science ®Google Scholar
• Rodríguez AM, Pascutti MF, Maeto C, Falivene J, Holgado MP, Turk G, Gherardi MM. IL-12 and GM-CSF in DNA/MVA immunizations against HIV-1 CRF12_BF Nef induced T-cell responses with an enhanced magnitude, breadth and quality. PLoS One 2012; 7:e37801; http://dx.doi.org/10.1371/journal.pone.0037801; PMID: 22655069
   PubMedGoogle Scholar
• Tapia E, Pérez-Jiménez E, López-Fuertes L, Gonzalo R, Gherardi MM, Esteban M. The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK. Microbes Infect 2003; 5:73 - 84; http://dx.doi.org/10.1016/S1286-4579(02)00077-1; PMID: 12650765
   PubMed Web of Science ®Google Scholar
• Gómez CE, Abaitua F, Rodríguez D, Esteban M. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma. Virus Res 2004; 105:11 - 22; http://dx.doi.org/10.1016/j.virusres.2004.04.008; PMID: 15325077
   PubMed Web of Science ®Google Scholar
• Bertley FM, Kozlowski PA, Wang SW, Chappelle J, Patel J, Sonuyi O, Mazzara G, Montefiori D, Carville A, Mansfield KG, et al. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunol 2004; 172:3745 - 57; http://dx.doi.org/10.4049/jimmunol.172.6.3745; PMID: 15004179
   PubMed Web of Science ®Google Scholar
• Dreicer R, Stadler WM, Ahmann FR, Whiteside T, Bizouarne N, Acres B, Limacher JM, Squiban P, Pantuck A. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs 2009; 27:379 - 86; http://dx.doi.org/10.1007/s10637-008-9187-3; PMID: 18931824
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, DeRaffele G, Mitcham J, Carroll MW, Harrop R, et al. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med 2009; 7:2; http://dx.doi.org/10.1186/1479-5876-7-2; PMID: 19128501
   PubMed Web of Science ®Google Scholar
• Kolibab K, Yang A, Derrick SC, Waldmann TA, Perera LP, Morris SL. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant. Clin Vaccine Immunol 2010; 17:793 - 801; http://dx.doi.org/10.1128/CVI.00006-10; PMID: 20357059
   PubMed Web of Science ®Google Scholar
• Li S, Qi X, Gao Y, Hao Y, Cui L, Ruan L, He W. IL-15 increases the frequency of effector memory CD8+ T cells in rhesus monkeys immunized with HIV vaccine. Cell Mol Immunol 2010; 7:491 - 4; http://dx.doi.org/10.1038/cmi.2010.44; PMID: 20871629
   PubMed Web of Science ®Google Scholar
• Oh S, Berzofsky JA, Burke DS, Waldmann TA, Perera LP. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci U S A 2003; 100:3392 - 7; http://dx.doi.org/10.1073/pnas.0630592100; PMID: 12626740
   PubMed Web of Science ®Google Scholar
• Perera LP, Waldmann TA, Mosca JD, Baldwin N, Berzofsky JA, Oh SK. Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice. J Virol 2007; 81:8774 - 83; http://dx.doi.org/10.1128/JVI.00538-07; PMID: 17553867
   PubMed Web of Science ®Google Scholar
• Perera PY, Derrick SC, Kolibab K, Momoi F, Yamamoto M, Morris SL, Waldmann TA, Perera LP. A multi-valent vaccinia virus-based tuberculosis vaccine molecularly adjuvanted with interleukin-15 induces robust immune responses in mice. Vaccine 2009; 27:2121 - 7; http://dx.doi.org/10.1016/j.vaccine.2009.01.132; PMID: 19356615
   PubMed Web of Science ®Google Scholar
• Poon LL, Leung YH, Nicholls JM, Perera PY, Lichy JH, Yamamoto M, Waldmann TA, Peiris JS, Perera LP. Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice. J Immunol 2009; 182:3063 - 71; http://dx.doi.org/10.4049/jimmunol.0803467; PMID: 19234203
   PubMed Web of Science ®Google Scholar
• Goulding J, Tahiliani V, Salek-Ardakani S. OX40:OX40L axis: emerging targets for improving poxvirus-based CD8(+) T-cell vaccines against respiratory viruses. Immunol Rev 2011; 244:149 - 68; http://dx.doi.org/10.1111/j.1600-065X.2011.01062.x; PMID: 22017437
   PubMed Web of Science ®Google Scholar
• Grosenbach DW, Schlom J, Gritz L, Gómez Yafal A, Hodge JW. A recombinant vector expressing transgenes for four T-cell costimulatory molecules (OX40L, B7-1, ICAM-1, LFA-3) induces sustained CD4+ and CD8+ T-cell activation, protection from apoptosis, and enhanced cytokine production. Cell Immunol 2003; 222:45 - 57; http://dx.doi.org/10.1016/S0008-8749(03)00080-7; PMID: 12798307
   PubMed Web of Science ®Google Scholar
• Liu J, Ngai N, Stone GW, Yue FY, Ostrowski MA. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine. Vaccine 2009; 27:5077 - 84; http://dx.doi.org/10.1016/j.vaccine.2009.06.046; PMID: 19573639
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, Remondo C, Cereda V, Jones JL, Pazdur MP, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008; 14:3060 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-08-0126; PMID: 18483372
   PubMed Web of Science ®Google Scholar
• Hodge JW, Higgins J, Schlom J. Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen. Vaccine 2009; 27:4475 - 82; http://dx.doi.org/10.1016/j.vaccine.2009.05.017; PMID: 19450631
   PubMed Web of Science ®Google Scholar
• Kudo-Saito C, Schlom J, Hodge JW. Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules. Clin Cancer Res 2004; 10:1090 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-03-0145; PMID: 14871989
   PubMed Web of Science ®Google Scholar
• Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, Niedzwiecki D, Panicali D, Schlom J, Lyerly HK. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 2005; 11:3017 - 24; http://dx.doi.org/10.1158/1078-0432.CCR-04-2172; PMID: 15837756
   PubMed Web of Science ®Google Scholar
• Palena C, Zhu M, Schlom J, Tsang KY. Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells. Blood 2004; 104:192 - 9; http://dx.doi.org/10.1182/blood-2003-09-3211; PMID: 15010371
   PubMed Web of Science ®Google Scholar
• Shankar P, Schlom J, Hodge JW. Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3). Vaccine 2001; 20:744 - 55; http://dx.doi.org/10.1016/S0264-410X(01)00409-1; PMID: 11738738
   PubMed Web of Science ®Google Scholar
• Zhu M, Terasawa H, Gulley J, Panicali D, Arlen P, Schlom J, Tsang KY. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res 2001; 61:3725 - 34; PMID: 11325845
   PubMed Web of Science ®Google Scholar
• Vasir B, Zarwan C, Ahmad R, Crawford KD, Rajabi H, Matsuoka K, Rosenblatt J, Wu Z, Mills H, Kufe D, et al. Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC). J Immunother 2012; 35:555 - 69; http://dx.doi.org/10.1097/CJI.0b013e31826a73de; PMID: 22892452
   PubMed Web of Science ®Google Scholar
• Gómez CE, Nájera JL, Sánchez R, Jiménez V, Esteban M. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens. Vaccine 2009; 27:3165 - 74; http://dx.doi.org/10.1016/j.vaccine.2009.03.049; PMID: 19446187
   PubMed Web of Science ®Google Scholar
• Lauterbach H, Pätzold J, Kassub R, Bathke B, Brinkmann K, Chaplin P, Suter M, Hochrein H. Genetic Adjuvantation of Recombinant MVA with CD40L Potentiates CD8 T Cell Mediated Immunity. Front Immunol 2013; 4:251; http://dx.doi.org/10.3389/fimmu.2013.00251; PMID: 23986761
   PubMed Web of Science ®Google Scholar
• Liu J, Yu Q, Stone GW, Yue FY, Ngai N, Jones RB, Kornbluth RS, Ostrowski MA. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals. Vaccine 2008; 26:4062 - 72; http://dx.doi.org/10.1016/j.vaccine.2008.05.018; PMID: 18562053
   PubMed Web of Science ®Google Scholar
• Parviainen S, Ahonen M, Diaconu I, Hirvinen M, Karttunen Å, Vähä-Koskela M, Hemminki A, Cerullo V. CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging. Gene Ther 2014; 21:195 - 204; http://dx.doi.org/10.1038/gt.2013.73; PMID: 24305418
   PubMed Web of Science ®Google Scholar
• Chavan R, Marfatia KA, An IC, Garber DA, Feinberg MB. Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses. J Virol 2006; 80:7676 - 87; http://dx.doi.org/10.1128/JVI.02748-05; PMID: 16840346
   PubMed Web of Science ®Google Scholar
• Lai L, Kwa S, Kozlowski PA, Montefiori DC, Ferrari G, Johnson WE, Hirsch V, Villinger F, Chennareddi L, Earl PL, et al. Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis 2011; 204:164 - 73; http://dx.doi.org/10.1093/infdis/jir199; PMID: 21628671
   PubMed Web of Science ®Google Scholar
• Lee JH, Roh MS, Lee YK, Kim MK, Han JY, Park BH, Trown P, Kirn DH, Hwang TH. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther 2010; 17:73 - 9; http://dx.doi.org/10.1038/cgt.2009.50; PMID: 19629143
   PubMed Web of Science ®Google Scholar
• Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 2013; 258:879 - 86; http://dx.doi.org/10.1097/SLA.0b013e318292919e; PMID: 23657083
   PubMed Web of Science ®Google Scholar
• Nemeckova S, Smahel M, Hainz P, Mackova J, Zurkova K, Gabriel P, Indrova M, Kutinova L. Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I molecules. Neoplasma 2007; 54:326 - 33; PMID: 17822323
   PubMed Web of Science ®Google Scholar
• Alcami A. Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol 2003; 3:36 - 50; http://dx.doi.org/10.1038/nri980; PMID: 12511874
   PubMed Web of Science ®Google Scholar
• Perdiguero B, Esteban M. The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res 2009; 29:581 - 98; http://dx.doi.org/10.1089/jir.2009.0073; PMID: 19708815
   PubMed Web of Science ®Google Scholar
• Smith GL, Benfield CT, Maluquer de Motes C, Mazzon M, Ember SW, Ferguson BJ, Sumner RP. Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. J Gen Virol 2013; 94:2367 - 92; http://dx.doi.org/10.1099/vir.0.055921-0; PMID: 23999164
   PubMed Web of Science ®Google Scholar
• Cottingham MG, Andersen RF, Spencer AJ, Saurya S, Furze J, Hill AV, Gilbert SC. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS One. 2008 Feb 20;3(2):e1638
   Google Scholar
• Falivene J, Del Médico Zajac MP, Pascutti MF, Rodríguez AM, Maeto C, Perdiguero B, Gómez CE, Esteban M, Calamante G, Gherardi MM. Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS One 2012; 7:e32220; http://dx.doi.org/10.1371/journal.pone.0032220; PMID: 22384183
   PubMed Web of Science ®Google Scholar
• García-Arriaza J, Arnáez P, Gómez CE, Sorzano CO, Esteban M. Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways. PLoS One 2013; 8:e66894; http://dx.doi.org/10.1371/journal.pone.0066894; PMID: 23826170
   PubMed Web of Science ®Google Scholar
• García-Arriaza J, Gómez CE, Sorzano CO, Esteban M. Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens. J Virol 2014; 88:3392 - 410; http://dx.doi.org/10.1128/JVI.02723-13; PMID: 24390336
   PubMed Web of Science ®Google Scholar
• García-Arriaza J, Nájera JL, Gómez CE, Sorzano CO, Esteban M. Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One 2010; 5:e12395; http://dx.doi.org/10.1371/journal.pone.0012395; PMID: 20811493
   PubMed Web of Science ®Google Scholar
• García-Arriaza J, Nájera JL, Gómez CE, Tewabe N, Sorzano CO, Calandra T, Roger T, Esteban M. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One 2011; 6:e24244; http://dx.doi.org/10.1371/journal.pone.0024244; PMID: 21909386
   PubMed Web of Science ®Google Scholar
• Gómez CE, Perdiguero B, Nájera JL, Sorzano CO, Jiménez V, González-Sanz R, Esteban M. Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol 2012; 86:5026 - 38; http://dx.doi.org/10.1128/JVI.06684-11; PMID: 22419805
   PubMed Web of Science ®Google Scholar
• Perdiguero B, Gómez CE, Di Pilato M, Sorzano CO, Delaloye J, Roger T, Calandra T, Pantaleo G, Esteban M. Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C. PLoS One 2013; 8:e74831; http://dx.doi.org/10.1371/journal.pone.0074831; PMID: 24069354
   PubMedGoogle Scholar
• Perdiguero B, Gómez CE, Nájera JL, Sorzano CO, Delaloye J, González-Sanz R, Jiménez V, Roger T, Calandra T, Pantaleo G, et al. Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens. PLoS One 2012; 7:e48524; http://dx.doi.org/10.1371/journal.pone.0048524; PMID: 23119046
   PubMed Web of Science ®Google Scholar
• Garber DA, O’Mara LA, Gangadhara S, McQuoid M, Zhang X, Zheng R, Gill K, Verma M, Yu T, Johnson B, et al. Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J Virol 2012; 86:12605 - 15; http://dx.doi.org/10.1128/JVI.00246-12; PMID: 22973033
   PubMed Web of Science ®Google Scholar
• Garber DA, O’Mara LA, Zhao J, Gangadhara S, An I, Feinberg MB. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies. PLoS One 2009; 4:e5445; http://dx.doi.org/10.1371/journal.pone.0005445; PMID: 19421328
   PubMed Web of Science ®Google Scholar
• Addo MM, Draenert R, Rathod A, Verrill CL, Davis BT, Gandhi RT, Robbins GK, Basgoz NO, Stone DR, Cohen DE, et al. Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS One 2007; 2:e321; http://dx.doi.org/10.1371/journal.pone.0000321; PMID: 17389912
   PubMedGoogle Scholar
• Hess C, Altfeld M, Thomas SY, Addo MM, Rosenberg ES, Allen TM, Draenert R, Eldrige RL, van Lunzen J, Stellbrink HJ, et al. HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet 2004; 363:863 - 6; http://dx.doi.org/10.1016/S0140-6736(04)15735-8; PMID: 15031033
   PubMed Web of Science ®Google Scholar
• Northfield JW, Loo CP, Barbour JD, Spotts G, Hecht FM, Klenerman P, Nixon DF, Michaëlsson J. Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T(EMRA) cells in early infection are linked to control of HIV-1 viremia and predict the subsequent viral load set point. J Virol 2007; 81:5759 - 65; http://dx.doi.org/10.1128/JVI.00045-07; PMID: 17376902
   PubMed Web of Science ®Google Scholar
• Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011; 473:523 - 7; http://dx.doi.org/10.1038/nature10003; PMID: 21562493
   PubMed Web of Science ®Google Scholar
• Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, Legasse AW, Axthelm MK, Oswald K, Trubey CM, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009; 15:293 - 9; http://dx.doi.org/10.1038/nm.1935; PMID: 19219024
   PubMed Web of Science ®Google Scholar
• García-Arriaza J, Cepeda V, Hallengärd D, Sorzano CO, Kümmerer BM, Liljeström P, Esteban M. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. J Virol 2014; 88:3527 - 47; http://dx.doi.org/10.1128/JVI.03418-13; PMID: 24403588
   PubMed Web of Science ®Google Scholar
• Wyatt LS, Earl PL, Vogt J, Eller LA, Chandran D, Liu J, Robinson HL, Moss B. Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines. Vaccine 2008; 26:486 - 93; http://dx.doi.org/10.1016/j.vaccine.2007.11.036; PMID: 18155813
   PubMed Web of Science ®Google Scholar
• Baur K, Brinkmann K, Schweneker M, Pätzold J, Meisinger-Henschel C, Hermann J, Steigerwald R, Chaplin P, Suter M, Hausmann J. Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses. J Virol 2010; 84:8743 - 52; http://dx.doi.org/10.1128/JVI.00604-10; PMID: 20538860
   PubMed Web of Science ®Google Scholar
• Moutaftsi M, Bui HH, Peters B, Sidney J, Salek-Ardakani S, Oseroff C, Pasquetto V, Crotty S, Croft M, Lefkowitz EJ, et al. Vaccinia virus-specific CD4+ T cell responses target a set of antigens largely distinct from those targeted by CD8+ T cell responses. J Immunol 2007; 178:6814 - 20; http://dx.doi.org/10.4049/jimmunol.178.11.6814; PMID: 17513729
   PubMed Web of Science ®Google Scholar
• Moutaftsi M, Tscharke DC, Vaughan K, Koelle DM, Stern L, Calvo-Calle M, Ennis F, Terajima M, Sutter G, Crotty S, et al. Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. Future Microbiol 2010; 5:221 - 39; http://dx.doi.org/10.2217/fmb.09.110; PMID: 20143946
   PubMed Web of Science ®Google Scholar
• Yang Z, Reynolds SE, Martens CA, Bruno DP, Porcella SF, Moss B. Expression profiling of the intermediate and late stages of poxvirus replication. J Virol 2011; 85:9899 - 908; http://dx.doi.org/10.1128/JVI.05446-11; PMID: 21795349
   PubMed Web of Science ®Google Scholar
• Moutaftsi M, Salek-Ardakani S, Croft M, Peters B, Sidney J, Grey H, Sette A. Correlates of protection efficacy induced by vaccinia virus-specific CD8+ T-cell epitopes in the murine intranasal challenge model. Eur J Immunol 2009; 39:717 - 22; http://dx.doi.org/10.1002/eji.200838815; PMID: 19224639
   PubMed Web of Science ®Google Scholar
• Geiben-Lynn R, Greenland JR, Frimpong-Boateng K, Letvin NL. Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responses. Clin Vaccine Immunol 2008; 15:691 - 6; http://dx.doi.org/10.1128/CVI.00418-07; PMID: 18272665
   PubMed Web of Science ®Google Scholar
• Pasquetto V, Bui HH, Giannino R, Banh C, Mirza F, Sidney J, Oseroff C, Tscharke DC, Irvine K, Bennink JR, et al. HLA-A*0201, HLA-A*1101, and HLA-B*0702 transgenic mice recognize numerous poxvirus determinants from a wide variety of viral gene products. J Immunol 2005; 175:5504 - 15; http://dx.doi.org/10.4049/jimmunol.175.8.5504; PMID: 16210659
   PubMed Web of Science ®Google Scholar
• Wilson EH, Hunter CA. Immunodominance and recognition of intracellular pathogens. J Infect Dis 2008; 198:1579 - 81; http://dx.doi.org/10.1086/593020; PMID: 18922096
   PubMed Web of Science ®Google Scholar
• Sette A, Grey H, Oseroff C, Peters B, Moutaftsi M, Crotty S, Assarsson E, Greenbaum J, Kim Y, Kolla R, et al. Definition of epitopes and antigens recognized by vaccinia specific immune responses: their conservation in variola virus sequences, and use as a model system to study complex pathogens. Vaccine 2009; 27:Suppl 6 G21 - 6; http://dx.doi.org/10.1016/j.vaccine.2009.10.011; PMID: 20006135
   PubMedGoogle Scholar
• Kastenmuller W, Gasteiger G, Gronau JH, Baier R, Ljapoci R, Busch DH, Drexler I. Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination. J Exp Med 2007; 204:2187 - 98; http://dx.doi.org/10.1084/jem.20070489; PMID: 17709425
   PubMed Web of Science ®Google Scholar
• Assarsson E, Greenbaum JA, Sundström M, Schaffer L, Hammond JA, Pasquetto V, Oseroff C, Hendrickson RC, Lefkowitz EJ, Tscharke DC, et al. Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. Proc Natl Acad Sci U S A 2008; 105:2140 - 5; http://dx.doi.org/10.1073/pnas.0711573105; PMID: 18245380
   PubMed Web of Science ®Google Scholar
• Yang Z, Bruno DP, Martens CA, Porcella SF, Moss B. Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proc Natl Acad Sci U S A 2010; 107:11513 - 8; http://dx.doi.org/10.1073/pnas.1006594107; PMID: 20534518
   PubMed Web of Science ®Google Scholar
• Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 1992; 89:10847 - 51; http://dx.doi.org/10.1073/pnas.89.22.10847; PMID: 1438287
   PubMed Web of Science ®Google Scholar
• Orubu T, Alharbi NK, Lambe T, Gilbert SC, Cottingham MG. Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA. PLoS One 2012; 7:e40167; http://dx.doi.org/10.1371/journal.pone.0040167; PMID: 22761956
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Sisler JR, Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 1997; 23:1094 - 7; PMID: 9421642
   PubMed Web of Science ®Google Scholar
• Cochran MA, Puckett C, Moss B. In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals. J Virol 1985; 54:30 - 7; PMID: 3973982
   PubMed Web of Science ®Google Scholar
• Wyatt LS, Shors ST, Murphy BR, Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 1996; 14:1451 - 8; http://dx.doi.org/10.1016/S0264-410X(96)00072-2; PMID: 8994321
   PubMed Web of Science ®Google Scholar
• Liu X, Kremer M, Broyles SS. A natural vaccinia virus promoter with exceptional capacity to direct protein synthesis. J Virol Methods 2004; 122:141 - 5; http://dx.doi.org/10.1016/j.jviromet.2004.08.009; PMID: 15542137
   PubMed Web of Science ®Google Scholar
• Di Pilato M, Mejías-Pérez E, Gómez CE, Perdiguero B, Sorzano CO, Esteban M. New vaccinia virus promoter as a potential candidate for future vaccines. J Gen Virol 2013; 94:2771 - 6; http://dx.doi.org/10.1099/vir.0.057299-0; PMID: 24077296
   PubMed Web of Science ®Google Scholar
• Isshiki M, Zhang X, Sato H, Ohashi T, Inoue M, Shida H. Effects of different promoters on the virulence and immunogenicity of a HIV-1 Env-expressing recombinant vaccinia vaccine. Vaccine 2014; 32:839 - 45; http://dx.doi.org/10.1016/j.vaccine.2013.12.022; PMID: 24370703
   PubMed Web of Science ®Google Scholar
• Wennier ST, Brinkmann K, Steinhäußer C, Mayländer N, Mnich C, Wielert U, Dirmeier U, Hausmann J, Chaplin P, Steigerwald R. A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses. PLoS One 2013; 8:e73511; http://dx.doi.org/10.1371/journal.pone.0073511; PMID: 23951355
   PubMed Web of Science ®Google Scholar
• Dai K, Liu Y, Liu M, Xu J, Huang W, Huang X, Liu L, Wan Y, Hao Y, Shao Y. Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes. Vaccine 2008; 26:5062 - 71; http://dx.doi.org/10.1016/j.vaccine.2008.06.011; PMID: 18573290
   PubMed Web of Science ®Google Scholar
• Huang X, Lu B, Yu W, Fang Q, Liu L, Zhuang K, Shen T, Wang H, Tian P, Zhang L, et al. A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS One 2009; 4:e4180; http://dx.doi.org/10.1371/journal.pone.0004180; PMID: 19159014
   PubMed Web of Science ®Google Scholar
• Nájera JL, Gómez CE, García-Arriaza J, Sorzano CO, Esteban M. Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One 2010; 5:e11406; http://dx.doi.org/10.1371/journal.pone.0011406; PMID: 20613977
   PubMedGoogle Scholar
• Vijaysri S, Jentarra G, Heck MC, Mercer AA, McInnes CJ, Jacobs BL. Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: intra-nasal vaccination. Vaccine 2008; 26:664 - 76; http://dx.doi.org/10.1016/j.vaccine.2007.11.045; PMID: 18096276
   PubMed Web of Science ®Google Scholar
• Kibler KV, Gomez CE, Perdiguero B, Wong S, Huynh T, Holechek S, Arndt W, Jimenez V, Gonzalez-Sanz R, Denzler K, et al. Improved NYVAC-based vaccine vectors. PLoS One 2011; 6:e25674; http://dx.doi.org/10.1371/journal.pone.0025674; PMID: 22096477
   PubMed Web of Science ®Google Scholar
• Quakkelaar ED, Redeker A, Haddad EK, Harari A, McCaughey SM, Duhen T, Filali-Mouhim A, Goulet JP, Loof NM, Ossendorp F, et al. Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One 2011; 6:e16819; http://dx.doi.org/10.1371/journal.pone.0016819; PMID: 21347234
   PubMed Web of Science ®Google Scholar
• Sánchez-Sampedro L, Gómez CE, Mejías-Pérez E, Pérez-Jiménez E, Oliveros JC, Esteban M. Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens. J Virol 2013; 87:6955 - 74; http://dx.doi.org/10.1128/JVI.03013-12; PMID: 23596295
   PubMed Web of Science ®Google Scholar
• Kennedy JS, Gurwith M, Dekker CL, Frey SE, Edwards KM, Kenner J, Lock M, Empig C, Morikawa S, Saijo M, et al. Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. J Infect Dis 2011; 204:1395 - 402; http://dx.doi.org/10.1093/infdis/jir527; PMID: 21921208
   PubMed Web of Science ®Google Scholar
• Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine 2006; 24:7009 - 22; http://dx.doi.org/10.1016/j.vaccine.2006.03.087; PMID: 17052815
   PubMed Web of Science ®Google Scholar
• Saito T, Fujii T, Kanatani Y, Saijo M, Morikawa S, Yokote H, Takeuchi T, Kuwabara N. Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA 2009; 301:1025 - 33; http://dx.doi.org/10.1001/jama.2009.289; PMID: 19278946
   PubMed Web of Science ®Google Scholar
• Xiao H, Liu L, Zhu Q, Tan Z, Yu W, Tang X, Zhan D, Du Y, Wang H, Liu D, et al. A replicating modified vaccinia tiantan strain expressing an avian-derived influenza H5N1 hemagglutinin induce broadly neutralizing antibodies and cross-clade protective immunity in mice. PLoS One 2013; 8:e83274; http://dx.doi.org/10.1371/journal.pone.0083274; PMID: 24358269
   PubMedGoogle Scholar
• Zhu R, Huang W, Wang W, Liu Q, Nie J, Meng S, Yu Y, Wang Y. Comparison on virulence and immunogenicity of two recombinant vaccinia vaccines, Tian Tan and Guang9 strains, expressing the HIV-1 envelope gene. PLoS One 2012; 7:e48343; http://dx.doi.org/10.1371/journal.pone.0048343; PMID: 23139778
   PubMed Web of Science ®Google Scholar
• Chan WM, Rahman MM, McFadden G. Oncolytic myxoma virus: the path to clinic. Vaccine 2013; 31:4252 - 8; http://dx.doi.org/10.1016/j.vaccine.2013.05.056; PMID: 23726825
   PubMed Web of Science ®Google Scholar
• Yang S, Carroll MW, Torres-Duarte AP, Moss B, Davidson EA. Addition of the MSA1 signal and anchor sequences to the malaria merozoite surface antigen 1 C-terminal region enhances immunogenicity when expressed by recombinant vaccinia virus. Vaccine 1997; 15:1303 - 13; http://dx.doi.org/10.1016/S0264-410X(97)00039-X; PMID: 9302735
   PubMed Web of Science ®Google Scholar
• Santra S, Liao HX, Zhang R, Muldoon M, Watson S, Fischer W, Theiler J, Szinger J, Balachandran H, Buzby A, et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010; 16:324 - 8; http://dx.doi.org/10.1038/nm.2108; PMID: 20173754
   PubMed Web of Science ®Google Scholar
• Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, Liu J, Abbink P, Maxfield LF, Seaman MS, et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 2013; 155:531 - 9; http://dx.doi.org/10.1016/j.cell.2013.09.061; PMID: 24243013
   PubMed Web of Science ®Google Scholar
• Hanke T. Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines. Expert Opin Biol Ther 2014; 14:601 - 16; http://dx.doi.org/10.1517/14712598.2014.885946; PMID: 24490585
   PubMed Web of Science ®Google Scholar
• Gómez CE, Nájera JL, Jiménez V, Bieler K, Wild J, Kostic L, Heidari S, Chen M, Frachette MJ, Pantaleo G, et al. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine 2007; 25:1969 - 92; http://dx.doi.org/10.1016/j.vaccine.2006.11.051; PMID: 17224219
   PubMed Web of Science ®Google Scholar
• Bart PA, Goodall R, Barber T, Harari A, Guimaraes-Walker A, Khonkarly M, Sheppard NC, Bangala Y, Frachette MJ, Wagner R, et al, EuroVacc Consortium. EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine 2008; 26:3153 - 61; http://dx.doi.org/10.1016/j.vaccine.2008.03.083; PMID: 18502002
   PubMed Web of Science ®Google Scholar
• García F, Bernaldo de Quirós JC, Gómez CE, Perdiguero B, Nájera JL, Jiménez V, García-Arriaza J, Guardo AC, Pérez I, Díaz-Brito V, et al. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine 2011; 29:8309 - 16; http://dx.doi.org/10.1016/j.vaccine.2011.08.098; PMID: 21907749
   PubMed Web of Science ®Google Scholar
• Gómez CE, Nájera JL, Perdiguero B, García-Arriaza J, Sorzano CO, Jiménez V, González-Sanz R, Jiménez JL, Muñoz-Fernández MA, López Bernaldo de Quirós JC, et al. The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. J Virol 2011; 85:11468 - 78; http://dx.doi.org/10.1128/JVI.05165-11; PMID: 21865377
   PubMed Web of Science ®Google Scholar
• Harari A, Bart PA, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008; 205:63 - 77; http://dx.doi.org/10.1084/jem.20071331; PMID: 18195071
   PubMed Web of Science ®Google Scholar
• McCormack S, Stöhr W, Barber T, Bart PA, Harari A, Moog C, Ciuffreda D, Cellerai C, Cowen M, Gamboni R, et al. EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008; 26:3162 - 74; http://dx.doi.org/10.1016/j.vaccine.2008.02.072; PMID: 18502003
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al, MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209 - 20; http://dx.doi.org/10.1056/NEJMoa0908492; PMID: 19843557
   PubMed Web of Science ®Google Scholar
• Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, Dugast AS, Schoen MK, Rolland M, Suscovich TJ, et al. Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines. Sci Transl Med. 2014 Mar 19;6(228):228ra38
   Google Scholar
• Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L, et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One 2013; 8:e75665; http://dx.doi.org/10.1371/journal.pone.0075665; PMID: 24086607
   PubMed Web of Science ®Google Scholar
• Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275 - 86; http://dx.doi.org/10.1056/NEJMoa1113425; PMID: 22475592
   PubMed Web of Science ®Google Scholar
• Yates NL, Liao HX, Fong Y, Decamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang ZY, Seaton KE, et al. Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination. Sci Transl Med. 2014;6(228):228ra39
   Google Scholar
• Zolla-Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA, et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One 2014; 9:e87572; http://dx.doi.org/10.1371/journal.pone.0087572; PMID: 24504509
   PubMed Web of Science ®Google Scholar
• McKay PF, Cope AV, Mann JF, Joseph S, Esteban M, Tatoud R, Carter D, Reed SG, Weber J, Shattock RJ. Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimen. PLoS One 2014; 9:e84707; http://dx.doi.org/10.1371/journal.pone.0084707; PMID: 24465426
   PubMed Web of Science ®Google Scholar
• Fouda GG, Amos JD, Wilks AB, Pollara J, Ray CA, Chand A, Kunz EL, Liebl BE, Whitaker K, Carville A, et al. Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk. J Virol 2013; 87:6986 - 99; http://dx.doi.org/10.1128/JVI.00528-13; PMID: 23596289
   PubMed Web of Science ®Google Scholar
• Pattacini L, Mize GJ, Graham JB, Fluharty TR, Graham TM, Lingnau K, Wizel B, Perdiguero B, Esteban M, Pantaleo G, et al. A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity. PLoS One 2012; 7:e42163; http://dx.doi.org/10.1371/journal.pone.0042163; PMID: 22848738
   PubMedGoogle Scholar
• Flynn BJ, Kastenmüller K, Wille-Reece U, Tomaras GD, Alam M, Lindsay RW, Salazar AM, Perdiguero B, Gomez CE, Wagner R, et al. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A 2011; 108:7131 - 6; http://dx.doi.org/10.1073/pnas.1103869108; PMID: 21467219
   PubMed Web of Science ®Google Scholar
• Collado M, Rodríguez D, Rodríguez JR, Vázquez I, Gonzalo RM, Esteban M. Chimeras between the human immunodeficiency virus (HIV-1) Env and vaccinia virus immunogenic proteins p14 and p39 generate in mice broadly reactive antibodies and specific activation of CD8+ T cell responses to Env. Vaccine 2000; 18:3123 - 33; http://dx.doi.org/10.1016/S0264-410X(00)00112-2; PMID: 10856792
   PubMed Web of Science ®Google Scholar
• Vijayan A, Gómez CE, Espinosa DA, Goodman AG, Sanchez-Sampedro L, Sorzano CO, Zavala F, Esteban M. Adjuvant-like effect of vaccinia virus 14K protein: a case study with malaria vaccine based on the circumsporozoite protein. J Immunol 2012; 188:6407 - 17; http://dx.doi.org/10.4049/jimmunol.1102492; PMID: 22615208
   PubMed Web of Science ®Google Scholar